Cabaletta Bio (NASDAQ:CABA) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Cabaletta Bio (NASDAQ:CABA - Free Report) in a research note issued to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a $25.00 target price on the stock. HC Wainwright also issued estimates for Cabaletta Bio's Q1 2025 earnings at ($0.63) EPS, Q2 2025 earnings at ($0.63) EPS, Q3 2025 earnings at ($0.65) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($2.51) EPS, FY2026 earnings at ($2.46) EPS, FY2027 earnings at ($2.45) EPS, FY2028 earnings at ($2.30) EPS and FY2029 earnings at ($2.00) EPS.

CABA has been the topic of a number of other research reports. Evercore ISI lowered Cabaletta Bio from an "outperform" rating to an "inline" rating and lowered their price target for the stock from $15.00 to $6.00 in a report on Friday, December 20th. Wells Fargo & Company cut shares of Cabaletta Bio from an "overweight" rating to an "equal weight" rating and dropped their price objective for the company from $12.00 to $6.00 in a research note on Thursday, December 19th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $21.00.

Remove Ads

Cabaletta Bio Trading Down 6.7 %

Shares of NASDAQ CABA traded down $0.08 during trading hours on Tuesday, reaching $1.11. The stock had a trading volume of 1,634,701 shares, compared to its average volume of 1,497,163. The firm has a 50-day moving average of $1.98 and a 200-day moving average of $2.89. The firm has a market cap of $56.32 million, a price-to-earnings ratio of -0.52 and a beta of 2.44. Cabaletta Bio has a fifty-two week low of $1.08 and a fifty-two week high of $19.04.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.65) EPS for the quarter, meeting the consensus estimate of ($0.65). On average, equities analysts predict that Cabaletta Bio will post -2.34 EPS for the current year.

Hedge Funds Weigh In On Cabaletta Bio

A number of institutional investors and hedge funds have recently made changes to their positions in CABA. LPL Financial LLC boosted its holdings in Cabaletta Bio by 15.6% during the fourth quarter. LPL Financial LLC now owns 42,386 shares of the company's stock worth $96,000 after buying an additional 5,716 shares in the last quarter. Intech Investment Management LLC raised its holdings in Cabaletta Bio by 42.2% during the fourth quarter. Intech Investment Management LLC now owns 20,203 shares of the company's stock worth $46,000 after purchasing an additional 5,999 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Cabaletta Bio during the third quarter worth $32,000. Point72 DIFC Ltd acquired a new stake in Cabaletta Bio in the third quarter valued at $33,000. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Cabaletta Bio by 6.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 125,845 shares of the company's stock worth $594,000 after buying an additional 7,518 shares during the last quarter.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.